Nordic Pharma, Inc.

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system. Nordic Pharma attending Kiawah Eye to share this innovation with ophthalmology leaders. Read more: https://bwnews.pr/459n2dZ

The Nordic Pharma team had a great time at ASCRS last week! Thanks to all who stopped by our booth! #LACRIFILL #NordicPharma #ASCRS

We want to give a big thank you to our panelists who spoke this weekend at ASCRS! We would also like to extend a thank you to everyone who joined us in discussing LACRIFILL® Canalicular Gel. #LACRIFILL #NordicPharma #ASCRS

Join us to discuss the future of dry eye treatment at ASCRS this weekend where we will be presenting data on LACRIFILL® Canalicular Gel. We are looking forward to discussing our latest novel dry eye treatment with everyone in attendance. Register while you still can! https://lnkd.in/g-rW275X #LACRIFILL #NordicPharma #ASCRS

ASCRS is almost upon us! We are inviting everyone to join us for our dry eye panel discussion. Our panelists are excited to speak on the future of dry eye intervention. Register at the link below for a discussion on Nordic Pharma’s latest innovation in dry eye, LACRIFILL® Canalicular Gel. https://lnkd.in/g-rW275X #LACRIFILL #NordicPharma #ASCRS

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., will be presenting data on LACRIFILL® Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Boston, MA on April 5-8, 2024. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system. Read more: https://lnkd.in/edzx8GcY #NordicPharma #ASCRS #LACRIFILL

Looking forward to ASCRS next weekend! Stop by Nordic Pharma’s panel discussion highlighting LACRIFILL® Canalicular Gel. LACRIFILL is changing practice and changing lives so this is a panel discussion you will not want to miss! https://lnkd.in/g-rW275X #LACRIFILL #NordicPharma #ASCRS

We have some exciting news! We will be presenting data on LACRIFILL® Canalicular Gel, a novel therapy for dry eye, at ASCRS this year. Register for our panel discussion and stop by booth #1245 to learn more. https://lnkd.in/g-rW275X #LACRIFILL #NordicPharma #ASCRS

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V. announced on March 14, 2024 that eminent oculoplastic surgeon John P. Fezza, MD will serve on its U.S. Medical Advisory Board (MAB) which includes Eric Donnenfeld, MD (New York), Richard Lindstrom, MD (Minnesota), Vance Thompson, MD (South Dakota), Preeya Gupta, MD (North Carolina), Paul Karpecki, OD (Kentucky), Lisa Nijm, MD, JD (Illinois), and Selina McGee, OD (Oklahoma). Read more: https://lnkd.in/eBk3y8Fj #NordicPharmaInc #NordicPharma

Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today that preeminent ophthalmologist Eric D. Donnenfeld, MD will Chair its U.S. Medical Advisory Board (MAB) which includes Richard Lindstrom, MD (Minnesota), Vance Thompson, MD (South Dakota), Preeya Gupta, MD (North Carolina), Paul Karpecki, OD (Kentucky), Lisa Nijm, MD, JD (Illinois), and Selina McGee, OD (Oklahoma). Read more: https://bwnews.pr/3wDjWBD #NordicPharma #Amring